• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vir Biotechnology Inc (NQ: VIR )

9.260 +1.770 (+23.63%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 7,288,839
Open 7.140
Bid (Size) 9.170 (5)
Ask (Size) 9.270 (1)
Prev. Close 7.490
Today's Range 7.120 - 9.740
52wk Range 7.120 - 13.09
Shares Outstanding 133,976,538
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
What You Missed On Wall Street This Past Friday
Today 6:00 EST
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 
Via Talk Markets
Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
October 31, 2024
From Vir Biotechnology, Inc.
Via Business Wire

Performance

YTD
-11.89%
-11.89%
1 Month
+19.64%
+19.64%
3 Month
+7.05%
+7.05%
6 Month
-9.44%
-9.44%
1 Year
+7.30%
+7.30%

More News

Read More
What's Next: Vir Biotechnology's Earnings Preview
October 30, 2024
Via Benzinga
Vir Biotechnology to Provide Business Update and Report Third Quarter 2024 Financial Results on October 31, 2024
October 17, 2024
From Vir Biotechnology, Inc.
Via Business Wire
Breaking Down Vir Biotechnology: 6 Analysts Share Their Views
August 02, 2024
Via Benzinga
Vir Biotechnology Announces Clinical Advances Across Hepatitis Delta and Hepatitis B Programs at AASLD’s The Liver Meeting® 2024
October 15, 2024
From Vir Biotechnology, Inc.
Via Business Wire
Vir Biotechnology to Participate in the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference
October 03, 2024
From Vir Biotechnology, Inc.
Via Business Wire
Vir Biotechnology Appoints Jason O’Byrne as Chief Financial Officer
September 10, 2024
From Vir Biotechnology Inc.
Via Business Wire
Vir Biotechnology Announces Closing of Exclusive Worldwide License Agreement With Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-Cell Engagers
September 09, 2024
From Vir Biotechnology, Inc.
Via Business Wire
Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031
September 04, 2024
Via FinancialNewsMedia
Exposures COVID-19
Vir Biotechnology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
August 22, 2024
From Vir Biotechnology, Inc.
Via Business Wire
VIR Stock Earnings: Vir Biotechnology Misses EPS, Misses Revenue for Q2 2024
August 01, 2024
Via InvestorPlace
Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031
September 04, 2024
From FN Media Group LLC
Via GlobeNewswire
Vir Biotechnology Reports Second Quarter 2024 Financial Results and Announces Strategic Restructuring to Prioritize Clinical-Stage Pipeline Opportunities
August 01, 2024
From Vir Biotechnology, Inc.
Via Business Wire
Vir Biotechnology Acts on Expanded Strategy of Powering the Immune System Through Exclusive Worldwide License Agreement with Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-cell Engagers
August 01, 2024
From Vir Biotechnology, Inc.
Via Business Wire
Vir Biotechnology Stock Reaches 80-Plus RS Rating Benchmark
July 26, 2024
Via Investor's Business Daily
Vir Biotechnology to Report Second Quarter 2024 Financial Results on August 1, 2024
July 18, 2024
From Vir Biotechnology, Inc.
Via Business Wire
3 Undervalued Biotech Gems With 200%+ Analyst Price Targets
July 04, 2024
Via InvestorPlace
Vir Biotechnology Receives FDA IND Clearance and Fast Track Designation for Tobevibart and Elebsiran for the Treatment of Chronic Hepatitis Delta Infection
June 26, 2024
From Vir Biotechnology, Inc.
Via Business Wire
Why Is Infectious Disease-Focused Vir Biotechnology Stock Trading Higher On Wednesday?
June 05, 2024
Via Benzinga
Ollie's Bargain Outlet Posts Upbeat Earnings, Joins Verint Systems, Guidewire Software And Other Big Stocks Moving Higher On Wednesday
June 05, 2024
Via Benzinga
Why Lands' End Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
June 05, 2024
Via Benzinga
Tobevibart Monotherapy and Combination Therapy with Elebsiran Achieved High Virologic Response and ALT Normalization in People Living with the Hepatitis Delta Virus After 12 and 24 Weeks of Treatment
June 05, 2024
From Vir Biotechnology, Inc.
Via Business Wire
Vir Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
May 29, 2024
From Vir Biotechnology, Inc.
Via Business Wire
Vir Biotechnology Appoints Mark Eisner, M.D., M.P.H. as Chief Medical Officer
May 29, 2024
From Vir Biotechnology, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap